Literature DB >> 12397044

2-Hydroxyestradiol attenuates renal disease in chronic puromycin aminonucleoside nephropathy.

Stevan P Tofovic1, Raghvendra Dubey, Eman M Salah, Edwin K Jackson.   

Abstract

It has been previously shown that 2-hydroxyestradiol (2-OHE) attenuates the development of renal disease in genetic nephropathy associated with obesity and the metabolic syndrome. The purpose of this study was to test the hypothesis that 2-OHE, irrespective of its effects on metabolic status and/or obesity, exerts direct renoprotective effects in vivo. First, the effects of increasing doses of 2-OHE on mesangial cell growth, proliferation, and collagen synthesis in isolated rat glomerular mesangial cells were evaluated in vitro. Second, the effects of 12-wk administration of 2-OHE (10 micro g/h per kg) on renal function and structure in chronic puromycin aminonucleoside (PAN)-induced nephropathy in rats were evaluated in vivo. 2-OHE concentration-dependently (0.001 to 1 micro mol/L; P < 0.001) inhibited serum (2.5%)-induced cell growth ((3)H-thymidine incorporation), collagen synthesis ((3)H-proline incorporation), and cell proliferation (cell number). Importantly, the inhibitory effects of 2-OHE (0.1 micro mol/L) were not blocked by ICI182780 (50 micro mol/L), an estrogen receptor antagonist. In vivo, chronic administration of PAN (75 mg/kg + 5 x 20 mg/kg) over 12 wk induced severe chronic renal disease. Chronic treatment with 2-OHE significantly (P < 0.05) attenuated PAN-induced decrease in glomerular filtration, reduced proteinuria, and the elevated BP, and it had no effect on PAN-induced increase in plasma cholesterol and triglycerides levels. 2-OHE had no effects on plasma testosterone levels in male nephropathic animals. Immunohistochemical staining for collagen IV and proliferating cell nuclear antigen (PCNA) in glomeruli and transforming growth factor-beta (TGF-beta) in renal tubular cells were significantly higher in PAN nephropatic rats versus control animals with intact kidneys. PAN also markedly increased glomerular and interstitial macrophage infiltration (ED1(+) cells). 2-OHE had no effects on renal tubular cell TGF-beta, but it significantly reduced glomerular PCNA and collagen IV and glomerular and interstitial macrophage infiltration. In summary, this study provides the first evidence that 2-OHE exerts direct renoprotective effects in vivo. These effects are mediated by estrogen receptor-independent mechanisms and are due, at least in part, to the inhibition of some of the key proliferative mechanisms involved in glomerular remodeling and sclerosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12397044     DOI: 10.1097/01.asn.0000031804.77546.f5

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  9 in total

1.  2-Hydroxyestradiol slows progression of experimental polycystic kidney disease.

Authors:  Sharon Anderson; Terry T Oyama; Jessie N Lindsley; William E Schutzer; Douglas R Beard; Vincent H Gattone; Radko Komers
Journal:  Am J Physiol Renal Physiol       Date:  2011-12-07

2.  2-Methoxyestradiol Attenuates Angiotensin II-Induced Hypertension, Cardiovascular Remodeling, and Renal Injury.

Authors:  Eman Salah; Sheldon I Bastacky; Edwin K Jackson; Stevan P Tofovic
Journal:  J Cardiovasc Pharmacol       Date:  2019-03       Impact factor: 3.105

Review 3.  The influence of gender and sexual hormones on incidence and outcome of chronic kidney disease.

Authors:  Sebastian Kummer; Gero von Gersdorff; Markus J Kemper; Jun Oh
Journal:  Pediatr Nephrol       Date:  2011-07-16       Impact factor: 3.714

4.  Predictors of end-stage renal disease in the urban poor.

Authors:  Yoshio N Hall; Andy I Choi; Ping Xu; Nicholas L Smith; Edward J Boyko
Journal:  J Health Care Poor Underserved       Date:  2013-11

5.  Estrogen receptor alpha expression in podocytes mediates protection against apoptosis in-vitro and in-vivo.

Authors:  Sebastian Kummer; Stefanie Jeruschke; Lara Vanessa Wegerich; Andrea Peters; Petra Lehmann; Annette Seibt; Friederike Mueller; Nadezda Koleganova; Elisabeth Halbenz; Claus Peter Schmitt; Markus Bettendorf; Ertan Mayatepek; Marie-Luise Gross-Weissmann; Jun Oh
Journal:  PLoS One       Date:  2011-11-11       Impact factor: 3.240

6.  An integrated lipidomics and metabolomics reveal nephroprotective effect and biochemical mechanism of Rheum officinale in chronic renal failure.

Authors:  Zhi-Hao Zhang; Nosratola D Vaziri; Feng Wei; Xian-Long Cheng; Xu Bai; Ying-Yong Zhao
Journal:  Sci Rep       Date:  2016-02-23       Impact factor: 4.379

7.  Effect of ovariectomy on the progression of chronic kidney disease-mineral bone disorder (CKD-MBD) in female Cy/+ rats.

Authors:  Colby J Vorland; Pamela J Lachcik; Elizabeth A Swallow; Corinne E Metzger; Matthew R Allen; Neal X Chen; Sharon M Moe; Kathleen M Hill Gallant
Journal:  Sci Rep       Date:  2019-05-28       Impact factor: 4.379

Review 8.  Gender, sex hormones and pulmonary hypertension.

Authors:  Eric D Austin; Tim Lahm; James West; Stevan P Tofovic; Anne Katrine Johansen; Margaret R Maclean; Abdallah Alzoubi; Masahiko Oka
Journal:  Pulm Circ       Date:  2013-04       Impact factor: 3.017

Review 9.  Prodrugs in cardiovascular therapy.

Authors:  Marinella G Sandros; Chady B Sarraf; Maryam Tabrizian
Journal:  Molecules       Date:  2008-05-14       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.